T-cell activation and cytokine production via a bispecific single-chain antibody fragment targeted to blood-stage malaria parasites

Blood

Volumn 101, Issue 6, 2003, Pages 2300-2306

  Yoshida, Shigeto ^a,b   Kobayashi, Tominari ^b   Matsuoka, Hiroyuki ^b   Seki, Chisato ^b   Gosnell, William L ^b   Chang, Sandra P ^b   Ishii, Akira ^b  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF HAWAII   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; EPITOPE; GAMMA INTERFERON; GLYCINE; OKT 3; SERINE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANTIGEN BINDING; ARTICLE; BACULOVIRUS; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG MECHANISM; DRUG SELECTIVITY; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HUMAN CELL; IN VIVO STUDY; LYMPHOCYTE ACTIVATION; MACROPHAGE; MALARIA; MEROZOITE; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; NUCLEOTIDE SEQUENCE; PHAGOCYTOSIS; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0037443396     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-03-0831     Document Type: Article

References (33)

1. World Health Organization. The World Health Report 1998. Life in the 21st century: a vision for all. Geneva, Switzerland: World Health Organization; 1998.
2. Mack M, Riethmuller G, Kufer P. A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc Natl Acad Sci U S A. 1995;92:7021-7025.
3. Loffler A, Kufer P, Lutterbuse R, et al. A recombinant bispecific single-chain antibody, CD19 × CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood. 2000;95:2098-2103.
4. Belani R, Weiner GJ. T cell activation and cytokine production in anti-CD3 bispecific antibody therapy. J Hematother. 1995;4:395-402.
5. George AJ, Titus JA, Jost CR, et al. Redirection of T cell-mediated cytotoxicity by a recombinant single-chain Fv molecule. J Immunol. 1994;152:1802-1811.
6. Barth S, Huhn M, Matthey B, et al. Ki-4(scFv)-ETA', a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice. Blood. 2000;95:3909-3914.
7. Tibben JG, Boerman OC, Massuger LF, Schijf CP, Claessens RA, Corstens FH. Pharmacokinetics, biodistribution and biological effects of intravenously administered bispecific monoclonal antibody OC/TR F(ab′)2 in ovarian carcinoma patients. Int J Cancer. 1996;66:477-483.
8. Canevari S, Stoter G, Arienti F, et al. Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. J Natl Cancer Inst. 1995;87:1463-1469.
9. De Gast GC, Haagen IA, Van Houten AA, et al. CD8 T cell activation after intravenous administration of CD3 × CD19 bispecific antibody in patients with non-Hodgkin lymphoma. Cancer Immunol Immunother. 1995;40:390-396.
10. + effectors to kill HIV-1-infected cells. J Hematother. 1995;4:439-446.
11. Traunecker A, Lanzavecchia A, Karjalainen K. Bispecific single chain molecules (Janusins) target cytotoxic lymphocytes on HIV infected cells. EMBO J. 1991;10:3655-3659.
12. Berg J, Lotscher E, Steimer KS, et al. Bispecific antibodies that mediate killing of cells infected with human immunodeficiency virus of any strain. Proc Natl Acad Sci U S A. 1991;88:4723-4727.
13. Chappel JA, Holder AA. Monoclonal antibodies that inhibit Plasmodium falciparum invasion in vitro recognise the first growth factor-like domain of merozoite surface protein-1. Mol Biochem Parasitol. 1993;60:303-311.
14. Kumar S, Yadava A, Keister DB, et al. Immunogenicity and in vivo efficacy of recombinant Plasmodium falciparum merozoite surface protein-1 in Aotus monkeys. Mol Med. 1995;1:325-332.
15. Hirunpetcharat C, Tian JH, Kaslow DC, et al. Complete protective immunity induced in mice by immunization with the 19-kilodalton carboxylterminal fragment of the merozoite surface protein-1 (MSP1 [19]) of Plasmodium yoelii expressed in Saccharomyces cerevisiae: correlation of protection with antigen-specific antibody titer, but not with effector CD4+ T cells. J Immunol. 1997;159:3400-3411.
16. Keitel WA, Kester KE, Atmar RL, et al. Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp1(19)) and T helper epitopes of tetanus toxoid. Vaccine. 1999;18:531-539.
17. Yoshida S, Matsuoka H, Luo E, et al. A single-chain antibody fragment specific for the Plasmodium berghei ookinete protein Pbs21 confers transmission blockade in the mosquito midgut. Mol Biochem Parasitol. 1999;104:195-204.
18. Trager W, Jensen JB. Human malaria parasites in continuous culture. Science. 1976;193:673-675.
19. Arakawa F, Kuroki M, Kuwahara M, et al. Cloning and sequencing of the VH and V kappa genes of an anti-CD3 monoclonal antibody, and construction of a mouse/human chimeric antibody. J Biochem. 1996;120:657-662.
20. Chang SP, Gibson HL, Lee-Ng CT, Barr PJ, Hui GS. A carboxyl-terminal fragment of Plasmodium falciparum gp195 expressed by a recombinant baculovirus induces antibodies that completely inhibit parasite growth. J Immunol. 1992;149:548-555.
21. Julius MH, Simpson E, Herzenberg LA. A rapid method for the isolation of functional thymus-derived murine lymphocytes. Eur J Immunol. 1973;3:645-649.
22. Salmon BL, Oksman A, Goldberg DE. Malaria parasite exit from the host erythrocyte: a two-step process requiring extraerythrocytic proteolysis. Proc Natl Acad Sci U S A. 2001;98:271-276.
23. Lambros C, Vanderberg JP. Synchronization of P. falciparum eythrocytic stages in culture. J Parasitol. 1976;65:418-420.
24. Bouharoun-Tayoun H, Attanath P, Sabchareon A, Chongsuphajaisiddhi T, Druilhe P, Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes. J Exp Med. 1990;172:1633-1641.
25. Chang SP, Nikaido CM, Hashimoto AC, Hashiro CQ, Yokota BT, Hui GS. Regulation of antibody specificity to Plasmodium falciparum merozoite surface protein-1 by adjuvant and MHC haplotype. J Immunol. 1994;152:3483-3490.
26. Gur H, Wacholtz MC, Davis LS, Geppert TD, Lipsky PE. Modulatory effect of aggregating the CD3 molecular complex on T cell activation. Cell Immunol. 1992;140:81-96.
27. Tsygankov AYu, Broker BM, Emmrich F. Inhibition of the anti-CD3-induced T cell proliferation by crosslinking of stimulatory antibodies in the presence of PMA and interleukin-2. Cell Immunol. 1992;140:97-111.
28. Kwiatkowski D, Cannon JG, Manogue KR, Ceraml A, Dinarello CA, Greenwood BM. Tumour necrosis factor production in Falciparum malaria and its association with schizont rupture. Clin Exp Immunol. 1989;77:361-366.
29. Peyron F, Vuillez JP, Barbe G, Boudin C, Picot S, Ambroise-Thomas P. Plasma levels of tumor necrosis factor during a longitudinal survey in an endemic area of malaria. Acta Trop. 1990;47:47-51.
30. Kumaratilake LM, Ferrante A. T-cell cytokines in malaria: their role in the regulation of neutrophil-and macrophage-mediated killing of Plasmodium falciparum asexual blood forms. Res Immunol. 1994;145:423-429.
31. Jensen JB. Malaria crisis forms: intraerythrocytic development derangement. In M. M. Stevenson, ed. Malaria: Host Reponses to Infection. Boca Raton, FL: CRC Press. 1989;109-126.
32. Bouharoun-Tayoun H, Oeuvray C, Lunel F, Druilhe P. Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages. J Exp Med. 1995;182:409-418.
33. Kufer P, Zettl F, Borschert K, Lutterbüse R, Kischel R, Riethmüller G. Minimal costimulatory requirements for T cell priming and TH1 differentiation: activation of naive human T lymphocytes by tumor cells armed with bifunctional antibody constructs. Cancer Immun. 2001;1:10-31.